NCT05667493
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatmentIonis Pharmaceuticals, Inc.
~1,400 participants
Updated 2026-04-17 on ClinicalTrials.gov
What's tested:Eplontersen
At a glance
Recruiting sites
0 of 134 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
Measured over Baseline up to 36 months
+3 more outcomes measured
Conditions
Where it's being run
134 sites across 53 statesJapan9
Australia8
Brazil7
Portugal7
France6
Italy6
Germany5
California4
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)Baseline up to 36 months
- Change From Baseline in Platelet CountBaseline up to 36 months
- Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)Baseline up to 36 months
- Change From Baseline in Urine Protein Creatinine Ratio (UPCR)Baseline up to 36 months